Cox analysis that lowered the p-value to 0.02 was not fully pre-specified.
Can you expand on what you mean by "not fully" versus "fully"?
I comprehend all your other arguments on the Cox analysis of 9902a except what you believe Dendreon should have done to make this analysis "fully" pre-specified.
Unless otherwise indicated, this is the personal viewpoint of David Miller and not necessarily that of Biotech Stock Research, LLC